NCT07255859Recruiting
AVIGA3 (Cohort 2.0)
AVIGA3: Using an 'Automated Vision Assessment and Impairment Detection Through Gaze Analysis' Through a Longitudinal, Open-labelled, Randomized Clinical Trial to Monitor Recurrence of Aged-related Macular Degeneration in a Home-based Setting (Cohort 2.0).
Source: ClinicalTrials.gov · Last updated 24 Jun 2026
Brief summary (registry, in English)
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate the AVIGA system through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 23 Jun 2025
- Start date
- 16 Jun 2025
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Tan Tock Seng Hospital
- Diseases
- Macular degeneration
- NCT number
- NCT07255859
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 16 Jun 2025 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any ocular surgery in the previous 3 months, or vitrectomy in the previous 12 months
- Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study
- Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye.
Other illness
- Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye
- History of idiopathic or autoimmune-associated uveitis in either eye
- Active ocular inflammation or suspected or active ocular or periocular infection in either eye.
Other
- Unable to understand verbal spoken instructions and demonstrate device functionality and implementation.
- Unable to turn on and connect the web-camera to a computer independently.
Who the study is looking for
- Subjects in the age group ≥ 50 to 99 years old.
- Both genders
- Able to understand verbal spoken instructions in British/American English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation.
- Able to turn on and connect the web-camera to a computer independently or with the help of family.
- Subjects undergoing treatment for Wet-AMD without any signs and symptoms of recurrence of active AMD (AMD recurrence: choroidal neovascularisation, intraretinal or subretinal fluid is present) with OCT lesion fluid volume more than 2 mm3 or ILM height more than 250µm.
- Ability to comply with the study protocol, in the investigator's judgment.
- Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments.
Age in the registry: 50 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tan Tock Seng Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.